Merit Medical Reports Strong 2025 Financials, Resolves SEC Inquiry, and Completes Strategic Acquisitions

summarizeSummary

Merit Medical Systems Inc. reported robust financial results for 2025, including double-digit revenue growth and improved EPS, alongside the positive resolution of a multi-year SEC inquiry and the expiration of a Corporate Integrity Agreement.

check_boxKey Events

• Strong Full-Year 2025 Financial Performance

  The company reported net sales of $1.516 billion for 2025, an 11.8% increase from 2024. Gross profit margin improved to 48.7% from 47.4% in the prior year. Net income rose to $128.5 million, or $2.13 diluted EPS, compared to $120.4 million, or $2.03 diluted EPS, in 2024.

• Significant Increase in Operating Cash Flow

  Cash flows provided by operating activities increased substantially to $297.4 million in 2025, up from $220.8 million in 2024, demonstrating strong operational cash generation.

• Resolution of SEC Inquiry and Corporate Integrity Agreement

  The SEC's Division of Enforcement concluded its inquiry into the company's China business activities in Q3 2025 without recommending enforcement action. Additionally, the five-year Corporate Integrity Agreement (CIA) with the OIG expired in October 2025, with formal completion signaled in January 2026, removing significant compliance burdens.

• Strategic Acquisitions and Divestiture

  In 2025, Merit Medical completed the Biolife Merger for $127.2 million and acquired the C2 CryoBalloon device from Pentax for $21.9 million. Post-year-end, on February 17, 2026, the company divested its Dual Cap product line for $28 million, indicating active portfolio management.

auto_awesomeAnalysis

Merit Medical Systems Inc. delivered a strong annual performance for 2025, marked by significant revenue growth, improved profitability, and increased cash flow from operations. The company also actively managed its portfolio through strategic acquisitions and a divestiture. A key positive development is the formal conclusion of the SEC inquiry into its China business activities without enforcement action and the expiration of its Corporate Integrity Agreement, removing significant regulatory overhangs. This comprehensive annual report follows the preliminary Q4 and full-year 2025 results announced in an 8-K on the same day, providing full audited details and additional strategic context.